Annual Securities Report — FY2025
What StemRIM Inc. reported for the period from 2025-08-01 to 2026-07-31.
Filed 2026-10-27View the original on EDINET
How much it says
37Thin
What moved here
9named for the first time
Its own wording
44terms
Which filing this is
25/ 25newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
For the fiscal year from 1 August 2025 to 31 July 2026, ステムリム filed a securities report stating that it had “no” revenue, while recording R&D expenses and a net loss for the fiscal year. It also updated disclosures on the progress of redasemtide clinical trials, including the completion of an additional Phase II trial, as well as information on R&D, governance and other matters.
Komori's summary of this document, not the document's own words.37Thin
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
64
Detailed
38
Thin
54
Typical
50
Typical
0
Almost nothing
0
Almost nothing
27
Almost nothing
13
Almost nothing
55
Typical
73
Detailed
R&D spend15億円Money spent making new things.
Cash left over-48億円Cash from the business, less what went into equipment.
Spent on equipment8百万円Plants, machines — things meant to last.
Employees70Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.